Reve Technologies, Inc. (BSSP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2014 | -441.36 Thousand USD | -134.2% |
| 2013 | -188.45 Thousand USD | -289.89% |
| 2012 | -48.33 Thousand USD | 47.3% |
| 2011 | -91.72 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2015 Q1 | -176.47 Thousand USD | 13.83% |
| 2015 Q2 | -474.94 Thousand USD | -169.12% |
| 2015 Q3 | -59.96 Thousand USD | 87.37% |
| 2014 Q2 | -115.74 Thousand USD | -106.41% |
| 2014 Q4 | -204.8 Thousand USD | -216.31% |
| 2014 Q3 | -64.74 Thousand USD | 44.06% |
| 2014 FY | -441.36 Thousand USD | -134.2% |
| 2014 Q1 | -56.07 Thousand USD | -3.9% |
| 2013 FY | -188.45 Thousand USD | -289.89% |
| 2013 Q4 | -53.97 Thousand USD | 37.41% |
| 2013 Q2 | -43.68 Thousand USD | -854.36% |
| 2013 Q1 | -4577.00 USD | 63.17% |
| 2013 Q3 | -86.22 Thousand USD | -97.41% |
| 2012 FY | -48.33 Thousand USD | 47.3% |
| 2012 Q3 | -10.8 Thousand USD | -6.3% |
| 2012 Q2 | -10.16 Thousand USD | 31.95% |
| 2012 Q1 | -14.93 Thousand USD | -103.51% |
| 2012 Q4 | -12.42 Thousand USD | -14.99% |
| 2011 Q2 | -10.21 Thousand USD | -71.03% |
| 2011 Q1 | -5975.00 USD | 0.0% |
| 2011 FY | -91.72 Thousand USD | 0.0% |
| 2011 Q3 | -68.18 Thousand USD | -567.27% |
| 2011 Q4 | -7340.00 USD | 89.24% |
| 2010 Q3 | -1274.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.833% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 30.208% |
| Nascent Biotech, Inc. | -2.08 Million USD | 78.858% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -6.231% |
| Qrons Inc. | -789.34 Thousand USD | 44.084% |
| Rebus Holdings, Inc. | -1.02 Million USD | 56.729% |
| Skye Bioscience, Inc. | -37.64 Million USD | 98.828% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.678% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.295% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 97.219% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 93.679% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 66.949% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.411% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 93.288% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -61.436% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.445% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 84.74% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 75.756% |
| Mesoblast Limited | -87.95 Million USD | 99.498% |
| Marizyme, Inc. | -65.34 Million USD | 99.325% |
| Genus plc | 7.9 Million USD | 105.587% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 95.948% |
| Pharming Group N.V. | -10.54 Million USD | 95.816% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 79.659% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 88.104% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 95.009% |
| ContraFect Corporation | -65.15 Million USD | 99.323% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 90.967% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 74.45% |
| IMV Inc. | -36.48 Million USD | 98.79% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 94.524% |
| MultiCell Technologies, Inc. | -380.07 USD | -116028.345% |
| ONE Bio Corp. | 8.67 Million USD | 105.087% |
| Accustem Sciences Inc. | -3.74 Million USD | 88.219% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.146% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 65.168% |
| Q BioMed Inc. | -2.05 Million USD | 78.492% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 88.177% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 81.462% |
| Biomind Labs Inc. | -1.21 Million USD | 63.653% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.261% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 85.77% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 94.415% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 77.357% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -2847.175% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 92.413% |
| GB Sciences, Inc. | -1.36 Million USD | 67.586% |
| Alpha Cognition Inc. | -13.77 Million USD | 96.795% |
| HST Global, Inc. | -146.21 Thousand USD | -201.873% |
| CSL Limited | 2.64 Billion USD | 100.017% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 74.847% |
| Halberd Corporation | -79.67 Thousand USD | -453.955% |
| Enzolytics Inc. | -2.17 Million USD | 79.724% |
| Agentix Corp. | -1.37 Million USD | 67.882% |
| Resverlogix Corp. | -3.61 Million USD | 87.774% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 86.083% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.85% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 550.377% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 106.374% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 88.891% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 85.415% |
| AVAX Technologies, Inc. | -6.41 Million USD | 93.118% |
| Zenith Capital Corp. | -10.59 Million USD | 95.835% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.538% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -1799.015% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 89.354% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -630.252% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 77.988% |
| Kadimastem Ltd | -3.3 Million USD | 86.655% |
| Helix BioMedix, Inc. | -1.05 Million USD | 58.206% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 88.443% |
| BioStem Technologies, Inc. | -8.48 Million USD | 94.797% |
| Oncology Pharma Inc. | - USD | Infinity% |
| LadRx Corporation | 400.44 Thousand USD | 210.22% |
| Cell Source, Inc. | -5.32 Million USD | 91.705% |
| Regen BioPharma, Inc. | 1.02 Million USD | 143.123% |
| Regen BioPharma, Inc. | 1.02 Million USD | 143.123% |
| NovAccess Global Inc. | -4.76 Million USD | 90.745% |
| Affymax, Inc. | -14.42 Million USD | 96.94% |
| Itoco Inc. | -1.86 Million USD | 76.385% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 90.065% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 73.555% |
| Mobile Lads Corp. | -2.26 Million USD | 80.499% |
| CytoDyn Inc. | -49.84 Million USD | 99.114% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -458.462% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -93.475% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 53.122% |
| SYBLEU INC | -180.3 Thousand USD | -144.792% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 72.632% |
| International Stem Cell Corporation | -131 Thousand USD | -236.923% |
| Bioxytran, Inc. | -4.28 Million USD | 89.688% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -713.254% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 82.556% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.082% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 79.122% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 43.479% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 86.068% |
| Neutra Corp. | -233.46 Thousand USD | -89.051% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 97.825% |
| PureTech Health plc | -65.69 Million USD | 99.328% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 97.925% |
| IXICO plc | -1.17 Million USD | 62.532% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 95.554% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.227% |
| CSL Limited | 2.64 Billion USD | 100.017% |
| Cellectis S.A. | -103.17 Million USD | 99.572% |